US Psoriatic Arthritis Treatment Market 2025 – 2034

<p><strong>Reports Description</strong> <p>As per the <strong>US Psoriatic Arthritis Treatment Market</strong> analysis conducted by the CMI team, the US psoriatic arthritis treatment market is expected to record a CAGR of <strong>9.87%</strong> from 2025 to 2034. In 2025, the market size was USD <strong>4.1 Billion</strong>. By 2034, the valuation is anticipated to reach USD <strong>9.31 Billion</strong>.</p></p> <h3>Overview</h3> <p>The rising prevalence of psoriatic arthritis is one of the major drivers of the US psoriatic arthritis treatment market. The disease is more prevalent amongst those already battling plaque psoriasis. As per Celgene Corporation, nearly 30% of patients contracting psoriasis end up developing an inflammatory condition called psoriatic arthritis.</p> <p>Stressful lifestyles causing the immune system’s overstimulation, an increasing aging population, and increased product approvals are the other factors contributing toward the growth of the US psoriatic arthritis treatment market.</p> <p>Psoriasis has been conventionally treated through phototherapy and various non-biologic disease-modifying agents such as cyclosporine and methotrexate, amongst others. The rise in research activities regarding large molecules has resulted in an upswing in the development of biosimilar drugs and biologics with improved effectiveness and positive outcomes of therapeutics. Increased expenses on the development of advanced therapies are another catalyst to the US psoriatic arthritis treatment market.</p> <h3>Key Trends & Drivers</h3> <ul> <li><strong>Increased Prevalence of Psoriatic Arthritis</strong></li> </ul> <p>Rise in incidences of psoriatic arthritis is expediting the US psoriatic arthritis treatment market. Research states that close to 1.5 million US citizens are suffering from psoriatic arthritis (PsA). These figures do promulgate the discovery of new treatments and bolster the pharmaceuticals sector. With the rise in the frequency of disease, demand for therapies is likely to increase. The other ground is early diagnosis.</p> <h3>What's trending in the US Psoriatic Arthritis Market?</h3> <p>Biologic drugs, i.e., the targeted protein-engineered therapies, are recommended due to their effectiveness in the reduction of PsA symptoms. The other trend is continual development of improved and new biologic drugs, with numerous promising candidates in clinical trials. Also, biologic delivery’s nature is such that parenteral (injectable) and systemic routes of administration do continue to dominate the market.</p> <h3>What would be Business Impact of the US tariffs on the US Psoriatic Arthritis Treatment market?</h3> <p>The US tariffs on active pharmaceutical ingredients (APIs), equipment, and the other inputs do increase the cost of psoriatic arthritis (PsA) treatments, thereby resulting in disruptions in the supply chain followed by higher prices for providers and patients and a reduction in the affordability of the essential medicines. The majority of generic manufacturers are feeling the impact. This could, in turn, deter the companies from investing more in the US market, though some of them are trying to stockpile.</p> <h3>Key Threats</h3> <ul> <li><strong>Adverse Reactions/Side-effects of Psoriatic Arthritis Treatment</strong></li> </ul> <p>The healthcare professionals are getting concerned about adverse reactions pertaining to psoriatic arthritis treatment. This may, in turn, slow down the market. Those suffering from adverse effects may stop taking the prescribed medicines, which may result in inadequate disease management. The demand from consumers may also decline with patients’ reluctance to continue with those therapies.</p> <h3>Opportunities</h3> <p>The recent lot of biologic products prescribed for PsA is likely to drive the US psoriatic arthritis treatment market twofold. Dermatologists are increasingly recommending them due to their effectiveness in cutting down on symptoms of disease. For example – Mirikizumab has shown 82% improvement in symptoms of psoriasis. Moreover, various key players are strategically collaborating to improve penetration of new products in the near future.</p> <h3>Category Wise Insights</h3> <p><strong>By Drug Class </strong></p> <ul> <li><strong>NSAIDs</strong></li> </ul> <p>NSAIDs are effective in the reduction of stiffness and joint pain characteristic of psoriatic arthritis. Various NSAIDs, such as naproxen and ibuprofen, are broadly available over-the-counter (OTC), thereby rendering them easily accessible as well as affordable for various patients. NSAIDs, for those battling PsA’s milder forms, do serve as an initial and at times sufficient course of treatment, thereby providing essential management of symptoms.</p> <ul> <li><strong>DMARDs</strong></li> </ul> <p>The DMARDs are expected to grow on a significant note during the forecast period. This could be owing to rising incidences of psoriatic arthritis, which are driving the utilization of targeted synthetic DMARDs. With improvement in diagnostic capabilities coupled with rising awareness amongst the healthcare professionals as well as patients, interventions with DMARDs at an earlier stage have turned out to be effective. Targeted synthetic DMARDs like phosphodiesterase 4 (PDE4) and Janus kinase (JAK) inhibitors expedite the US psoriatic arthritis treatment market further. Such agents do offer notable therapeutic value with oral administration.</p> <ul> <li><strong>Biologics</strong></li> </ul> <p>Biologics dominate the US psoriatic arthritis treatment industry by accounting for over 40% of the overall market share. It is also expected to witness the highest CAGR during the forecast period. This could be due to the fact that biologics are reshaping the overall landscape of treatment by proffering targeted approaches to noticeably improve skin lesions, joint symptoms, and quality of life on the whole.</p> <p>The ability of biologics to modulate specified immune pathways such as TMF, IL-23, and IL-17 does make them particularly effective for the patients who respond weakly to conventional DMARDs (Disease-Modifying Anti-Rheumatic Drugs). Dominance on their part also reflects the continuous rollout of new biologics with longer dosing intervals and better safety profiles, which improve patient compliance.</p> <p><strong>By Type </strong></p> <ul> <li><strong>Prescriptions</strong></li> </ul> <p>Prescriptions account for over 80% of the market share. This could be reasoned with the complex and chronic nature of psoriatic arthritis, which does necessitate specialist-guided, long-term pharmacological interventions. A prescription is needed for both – targeted synthetic DMARDs and biologics. Such therapies are specifically initiated by rheumatologists, thereby reinforcing the significance of treatment pathways based on prescription.</p> <ul> <li><strong>OTC</strong></li> </ul> <p>The OTC sector is driven by a rise in focus on symptom management and self-care amongst the patients having mild-moderate manifestations of psoriatic arthritis. With the disease and its treatment revolving around public awareness, various individuals are resorting to non-prescription alternatives such as anti-inflammatory creams, topical analgesics, and supplements for adjunctive or initial relief.</p> <p><strong>Route of Administration </strong></p> <ul> <li><strong>Topical</strong></li> </ul> <p>Topical administration does provide a localized, first-line, and accessible option of treatment for mild-to-moderate cases, thereby improving patient compliance with novel non-greasy foams and formulations. Such formulations do offer a reduction in side effects in comparison with systematic treatments and are affordable, convenient, and available as OTC medications for use at home.</p> <ul> <li><strong>Oral</strong></li> </ul> <p>The oral sector is gaining momentum owing to ease of administration, strong efficacy profiles, and cost-efficiency pertaining to oral administration. Oral medications, unlike biologics, do not require infusion or injection, which results in them offering a higher level of adherence and convenience on the part of patients, especially the ones who are looking for invasive long-term treatment regimens. Increased availability of such agents, along with safety data from the recent clinical trials, is further improving their appeal amongst patients and clinicians alike.</p> <ul> <li><strong>Injectables</strong></li> </ul> <p>Injectables hold more than 50% of the market share. The injectables are favoured due to their targeted mechanism of proven efficiency and action in exercising control over skin and joint symptoms linked with psoriatic arthritis. The agents like TNF inhibitors (e.g., etanercept, adalimumab) and IL-23/IL-17 inhibitors are looked upon as the treatment’s mainstays, particularly in moderate-to-severe cases.</p> <h3>How is AI impacting the US Psoriatic Arthritis Treatment Market?</h3> <p>Scientists use various digital platforms driven by AI for combing through genetic clinical information, resulting in precision medicine for treating psoriatic arthritis. Furthermore, using AI models helps clinical trial teams in finding apt patient groups and predicting responses of patients to treatment, thereby cutting down on trial failures.</p> <p><strong>Report Scope</strong></p> <table> <tbody> <tr> <td><strong>Feature of the Report</strong></td> <td><strong>Details</strong></td> </tr> <tr> <td>Market Size in 2025</td> <td>USD 4.1 Billion</td> </tr> <tr> <td>Projected Market Size in 2034</td> <td>USD 9.31 Billion</td> </tr> <tr> <td>Market Size in 2024</td> <td>USD 3.64 Billion</td> </tr> <tr> <td>CAGR Growth Rate</td> <td>9.87% CAGR</td> </tr> <tr> <td>Base Year</td> <td>2024</td> </tr> <tr> <td>Forecast Period</td> <td>2025-2034</td> </tr> <tr> <td>Key Segment</td> <td>By Drug Class, Type, Route of Administration and Region</td> </tr> <tr> <td>Report Coverage</td> <td>Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends</td> </tr> <tr> <td>Regional Scope</td> <td>North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America</td> </tr> <tr> <td>Buying Options</td> <td>Request tailored purchasing options to fulfil your requirements for research.</td> </tr> </tbody> </table> <h3>Key Developments</h3> <p>The <a href="https://custommarketinsights.com/press-releases/us-psoriatic-arthritis-treatment-market-size/">US psoriatic arthritis treatment market</a> is witnessing a significant organic and inorganic expansion. Some of the key developments include -</p> <ul> <li>In February 2024, Biocon Biologics (a subsidiary of Biocon) announced that it had inked a settlement and licensing agreement with Janssen Biotech Inc. and Johnson & Johnson (jointly referred to as Janssen), which helped for the commercialization of Bmab 1200 (a potential biosimilar of Stelara) in the US.</li> </ul> <ul> <li>In October 2023, <a href="https://www.novartis.com/">Novartis</a> received approval from the US FDA for Cosentyx’s intravenous formulation, thereby extending its indication to treat adults suffering from psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis.</li> </ul> <h3>Leading Players</h3> <p>The US psoriatic arthritis treatment market is highly competitive, with a large number of service providers globally. Some of the key players in the market include:</p> <ul> <li>Novartis</li> <li>Bristol-Myers Squibb</li> <li>AbbVie</li> <li>Pfizer</li> <li>Johnson & Johnson Services Inc.</li> <li>Amgen Inc.</li> <li>Eli Lilly and Company</li> <li>Others</li> </ul> <p>These firms apply a plethora of strategies to enter the market, including innovations, mergers and acquisitions, and collaboration. The US psoriatic arthritis treatment market is shaped by the presence of diversified players that compete based on product innovation, vertical integration, and cost efficiency.</p> <p>The <strong>US Psoriatic Arthritis Treatment Market</strong> is segmented as follows:</p> <p><strong>By Drug Class </strong></p> <ul> <li>NSAIDs</li> <li>DMARD</li> <li>Biologics</li> </ul> <p><strong>By Type </strong></p> <ul> <li>Prescriptions</li> <li>OTC</li> </ul> <p><strong>By Route of Administration </strong></p> <ul> <li>Topical</li> <li>Oral</li> <li>Injectable</li> </ul>